CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 6.2

ph-index = 7

Forward Citations = 85(Granted Patents)

Location History:

Palo Alto, CA (US) (2010 - 2016)
Foster City, CA (US) (2015 - 2022)

Company Filing History:

23 out of 488

Rigel Pharmaceuticals, Incorporated

patents

2 out of 3,684

Bristol-myers Squibb Compnay

patents

1 out of 41

Bristol Meyers Squibb Company

patents

4. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2022

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11352360 - TGF-beta inhibitors (2022-06-07),

2. 10287295 - TGF-β inhibitors (2019-05-14),

3. 9884868 - TGF-beta inhibitors (2018-02-06),

4. 9624229 - Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases (2017-04-18),

5. 9353111 - Carboxamide compounds and methods for using the same (2016-05-31),

6. 9255085 - Carboxamide compounds and methods for using the same (2016-02-09),

7. 9181220 - N-substituted-heterocycloalkyloxybenzamide compounds and methods of use (2015-11-10),

8. 9174964 - AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same (2015-11-03),

9. 9062052 - Carboxamide compounds and methods for using the same (2015-06-23),

10. 8895578 - Carboxamide, sulfonamide and amine compounds and methods for using the same (2014-11-25),

11. 8871770 - Carboxamide compounds and methods for using the same (2014-10-28),

12. 8846600 - Carboxamide compounds and methods for using the same (2014-09-30),

13. 8785449 - Carboxamide compounds and methods for using the same (2014-07-22),

14. 8735418 - Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases (2014-05-27),

15. 8697727 - N-substituted-heterocycloalkyloxybenzamide compounds and methods of use (2014-04-15),

Title: Innovations by Hui Hong in Pharmaceutical Patents

Introduction: Hui Hong, based in Palo Alto, California, is a notable inventor with a remarkable portfolio of 24 patents. His contributions to the field of pharmaceuticals are particularly significant, focusing on compounds that hold potential in treating various diseases by targeting TGF-beta signaling pathways.

Latest Patents: Among his latest innovations are TGF-beta inhibitors, which include imidazole and thiazole compounds. These patents disclose specific pharmaceutical compositions and methods for their use. One notable embodiment involves a compound with a defined structure and its pharmaceutically acceptable salts, prodrugs, and N-oxides, including solvates and hydrates. This invention aims to inhibit TGF-beta, showcasing the potential to treat diseases by effectively blocking TGF-beta signaling.

Career Highlights: Hui Hong has made impactful contributions while working at renowned companies such as Rigel Pharmaceuticals and Bristol-Myers Squibb Company. His experience in these firms has equipped him with extensive knowledge and expertise in pharmaceutical research and development, further enhancing his innovative capabilities.

Collaborations: Hui has collaborated with several talented individuals throughout his career, including Rajinder Paul Singh and Ihab S. Darwish. These partnerships have played a crucial role in fostering advancements in his research and innovations, particularly in the realm of therapeutics targeting critical biological pathways.

Conclusion: Hui Hong's innovations, reflected in his extensive patent portfolio, demonstrate his commitment to advancing pharmaceutical science. His work on TGF-beta inhibitors represents a significant step toward developing new treatment options for diseases, showcasing his importance in the field of medical research and patenting.

This text is generated by artificial intelligence and may not be accurate.